MMP9 and fragile X syndrome: In this study, we have investigated whether plasma abundance levels of RAS, HK1, and MMP9 were sensitive to metformin treatment in individuals with FXS and whether they correlated with changes in commonly used clinical measures particularly Clinical Global Impression (CGI) and Body Mass Index (BMI).